Researchers are collecting genomic and clinical data on cancer patients outside of clinical trials to understand tumor biology, treatment efficacy, and care gaps.
The agreement is part of Biocartis' long term plans to expand its presence in the oncology field by building a menu of tests for immunotherapies.
Thrive Earlier Detection is banking on targeted detection of frequent cancer mutations, coupled with protein markers, while competitors turn to genome-wide approaches.
Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.
Never smokers make up an increasing portion of lung cancer patients, and researchers are working to tease out their genetic and environmental risk.
Caris will use its whole-transcriptome sequencing assay and Molecular Intelligence Trials service to identify patients for a phase II clinical trial.
This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.
Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form.
Tissue-agnostic drug development approaches have their own set of scientific and financial considerations, but some drugmakers are taking on those challenges.
Researchers used a genome-scale CRISPRi platform to identify genetic interactions with an inhibitor for a mutant form of KRAS in models of lung and pancreatic cancer.
The researchers have used nCounter, an FDA-cleared platform from NanoString Technologies, to develop their gene expression assay for subtype classification.
The California-based health system is expanding its partnership with clinical decision support vendor CancerIQ to integrate risk assessment into the Cerner EHR workflow.
Using exome sequencing, the team developed a transgenic model with altered orthologs of nine genes and found a combination of drugs that could act as a cancer treatment option.
With exome sequences from more than 600 metastatic breast tumors, researchers identified genomic alterations related to tumor progression, treatment response, and patient outcomes.
Standards for interoperability and better cooperation among stakeholders will help unleash the power of genomics in cancer care, says the head of the Biden Cancer Initiative.
MammaPrint classifies patients as either high risk or low risk of recurrence over a 10-year period while BluePrint classifies patients by breast cancer subtype.
The company formerly known as TransMed Systems looks to bring "clarity and transparency" to the emerging field of precision oncology and in patient-trial matching.
FLX Bio will apply Personalis' ImmunoID Next platform as part of a Phase I/II clinical trial evaluating its FLX475 drug in cancer therapy.
The firm launched a study this year to validate the new CRC-specific immune-transcriptomic assay, aiming to obtain regulatory approval in Europe.
The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.